What Clorox’s Index Additions and Leadership Changes Mean for Investors
Clorox (CLX) has just been added to both the Russell 2500 and Russell 2500 Value indexes, while also reshuffling senior leadership, giving investors fresh reasons to reassess how the stock fits in a portfolio.
See our latest analysis for Clorox.
Over the past month Clorox has seen a 6.02% 1 month share price return and a 3.02% 7 day share price return, yet the 1 year total shareholder return is down 19.26% and the 5 year total shareholder return is down 37.58%. This indicates that recent momentum contrasts with a weaker longer term record as investors weigh index inclusion and leadership changes.
If these shifts have you reviewing your watchlist, it could be a useful moment to see what else is moving and uncover 20 top founder-led companies
With Clorox shares down over the past year yet trading at an estimated 40% discount to one intrinsic value model and below the average analyst target, the key question is simple: is this a reset buying opportunity, or is the market already pricing in future growth?
Most Popular Narrative: 9.4% Undervalued
The most followed narrative values Clorox at $105.29 per share, compared with the last close of $95.44. It frames the stock as modestly undervalued and heavily dependent on execution in its core business and new health focused areas.
The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs, which should support margin expansion and sustained earnings growth once short-term transition noise normalizes.
Want to see what sits behind that margin story for Clorox? The narrative leans on measured revenue growth, stable profitability and a future earnings multiple that has to do some heavy lifting. The tension between cautious growth assumptions and a reduced valuation bar is where the fair value case really takes shape.
Result: Fair Value of $105.29 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Clorox still faces slow category growth and intense price competition in areas like Glad and cat litter. This could pressure margins and challenge this fair value narrative.
Find out about the key risks to this Clorox narrative.
Next Steps
Given the mix of concerns and optimism around Clorox, it makes sense to review the underlying data yourself and consider your options before sentiment shifts again. A good place to start is with a clear look at 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Clorox?
If you want to keep building on the work you have done with Clorox, use Simply Wall Street's screener to surface other opportunities that fit your style.
- Zero in on quality companies trading below their estimated worth by running a focused search through 43 high quality undervalued stocks
- Strengthen the income side of your portfolio by lining up stocks known for reliable, higher-yield payouts using 10 dividend fortresses
- Prioritize resilience by filtering for companies that pair solid finances with lower overall risk scores via 74 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com